File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Risk factors and outcomes of extended-spectrum beta-lactamase-producing E. coli peritonitis in CAPD patients
  • Basic View
  • Metadata View
  • XML View
TitleRisk factors and outcomes of extended-spectrum beta-lactamase-producing E. coli peritonitis in CAPD patients
 
AuthorsYip, T1
Tse, KC1
Lam, MF1
Tang, S1
Li, FK1
Choy, BY1
Lui, SL1
Chan, TM1
Lai, KN1
Lo, WK1
 
KeywordsCephalosporin
E coli
Extended-spectrum beta-lactamase
Gastric acid inhibitor
Peritonitis
 
Issue Date2006
 
PublisherMultimed, Inc. The Journal's web site is located at http://pdiconnect.com
 
CitationPeritoneal Dialysis International, 2006, v. 26 n. 2, p. 191-197 [How to Cite?]
 
Abstract◆ Objective: To determine the risk factors and outcomes of peritonitis caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli in continuous ambulatory peritoneal dialysis (CAPD). ◆ Patients and Methods: Episodes of E. coli CAPD peritonitis in our unit from October 1994 to August 2003 were reviewed. Demographic data, underlying medical conditions, recent use of gastric add inhibitors (including H2 antagonist and proton pump inhibitor), recent antibiotic therapy, antibiotic regimen for peritonitis episodes, sensitivity test results of the E. coli isolated, and clinical outcomes were examined. ◆ Results: Over a 10-year study period, 88 episodes of E. coli peritonitis were recorded; 11 of the 88 cases were caused by ESBL-producing E. coli. Recent use of cephalosporins and gastric acid inhibitor were associated with the development of ESBL-producing E. coli peritonitis. Compared with non-ESBL-produdng E. coli peritonitis, more cases in the ESBL-producing E. coli group developed treatment failure (45.5% vs 13.0%, p = 0.02) and died of sepsis (27.3% vs 3.9%, p = 0.02). Peritoneal failure rate was higher in the ESBL-producing E. coli group, although the difference was not statistically significant (18.2% vs 3.9%, p = 0.12). ◆ Conclusion: Peritonitis caused by ESBL-producing E. coli is associated with worse clinical outcomes. The use of cephalosporins and gastric acid inhibitors may contribute to its development. Further studies are warranted to investigate and determine the predisposing factors for ESBL-producing E. coli peritonitis. Copyright © 2006 International Society for Peritoneal Dialysis.
 
ISSN0896-8608
2013 Impact Factor: 2.199
2013 SCImago Journal Rankings: 1.189
 
ISI Accession Number IDWOS:000237003600013
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorYip, T
 
dc.contributor.authorTse, KC
 
dc.contributor.authorLam, MF
 
dc.contributor.authorTang, S
 
dc.contributor.authorLi, FK
 
dc.contributor.authorChoy, BY
 
dc.contributor.authorLui, SL
 
dc.contributor.authorChan, TM
 
dc.contributor.authorLai, KN
 
dc.contributor.authorLo, WK
 
dc.date.accessioned2012-09-05T05:25:53Z
 
dc.date.available2012-09-05T05:25:53Z
 
dc.date.issued2006
 
dc.description.abstract◆ Objective: To determine the risk factors and outcomes of peritonitis caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli in continuous ambulatory peritoneal dialysis (CAPD). ◆ Patients and Methods: Episodes of E. coli CAPD peritonitis in our unit from October 1994 to August 2003 were reviewed. Demographic data, underlying medical conditions, recent use of gastric add inhibitors (including H2 antagonist and proton pump inhibitor), recent antibiotic therapy, antibiotic regimen for peritonitis episodes, sensitivity test results of the E. coli isolated, and clinical outcomes were examined. ◆ Results: Over a 10-year study period, 88 episodes of E. coli peritonitis were recorded; 11 of the 88 cases were caused by ESBL-producing E. coli. Recent use of cephalosporins and gastric acid inhibitor were associated with the development of ESBL-producing E. coli peritonitis. Compared with non-ESBL-produdng E. coli peritonitis, more cases in the ESBL-producing E. coli group developed treatment failure (45.5% vs 13.0%, p = 0.02) and died of sepsis (27.3% vs 3.9%, p = 0.02). Peritoneal failure rate was higher in the ESBL-producing E. coli group, although the difference was not statistically significant (18.2% vs 3.9%, p = 0.12). ◆ Conclusion: Peritonitis caused by ESBL-producing E. coli is associated with worse clinical outcomes. The use of cephalosporins and gastric acid inhibitors may contribute to its development. Further studies are warranted to investigate and determine the predisposing factors for ESBL-producing E. coli peritonitis. Copyright © 2006 International Society for Peritoneal Dialysis.
 
dc.description.natureLink_to_OA_fulltext
 
dc.identifier.citationPeritoneal Dialysis International, 2006, v. 26 n. 2, p. 191-197 [How to Cite?]
 
dc.identifier.epage197
 
dc.identifier.hkuros117896
 
dc.identifier.isiWOS:000237003600013
 
dc.identifier.issn0896-8608
2013 Impact Factor: 2.199
2013 SCImago Journal Rankings: 1.189
 
dc.identifier.issue2
 
dc.identifier.pmid16623424
 
dc.identifier.scopuseid_2-s2.0-33645510764
 
dc.identifier.spage191
 
dc.identifier.urihttp://hdl.handle.net/10722/162957
 
dc.identifier.volume26
 
dc.languageeng
 
dc.publisherMultimed, Inc. The Journal's web site is located at http://pdiconnect.com
 
dc.publisher.placeCanada
 
dc.relation.ispartofPeritoneal Dialysis International
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAged
 
dc.subject.meshEscherichia Coli - Enzymology
 
dc.subject.meshEscherichia Coli Infections
 
dc.subject.meshHumans
 
dc.subject.meshMale
 
dc.subject.meshMiddle Aged
 
dc.subject.meshPeritoneal Dialysis, Continuous Ambulatory
 
dc.subject.meshPeritonitis - Microbiology
 
dc.subject.meshRisk Factors
 
dc.subject.meshBeta-Lactamases - Biosynthesis
 
dc.subjectCephalosporin
 
dc.subjectE coli
 
dc.subjectExtended-spectrum beta-lactamase
 
dc.subjectGastric acid inhibitor
 
dc.subjectPeritonitis
 
dc.titleRisk factors and outcomes of extended-spectrum beta-lactamase-producing E. coli peritonitis in CAPD patients
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Yip, T</contributor.author>
<contributor.author>Tse, KC</contributor.author>
<contributor.author>Lam, MF</contributor.author>
<contributor.author>Tang, S</contributor.author>
<contributor.author>Li, FK</contributor.author>
<contributor.author>Choy, BY</contributor.author>
<contributor.author>Lui, SL</contributor.author>
<contributor.author>Chan, TM</contributor.author>
<contributor.author>Lai, KN</contributor.author>
<contributor.author>Lo, WK</contributor.author>
<date.accessioned>2012-09-05T05:25:53Z</date.accessioned>
<date.available>2012-09-05T05:25:53Z</date.available>
<date.issued>2006</date.issued>
<identifier.citation>Peritoneal Dialysis International, 2006, v. 26 n. 2, p. 191-197</identifier.citation>
<identifier.issn>0896-8608</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/162957</identifier.uri>
<description.abstract>&#9670; Objective: To determine the risk factors and outcomes of peritonitis caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli in continuous ambulatory peritoneal dialysis (CAPD). &#9670; Patients and Methods: Episodes of E. coli CAPD peritonitis in our unit from October 1994 to August 2003 were reviewed. Demographic data, underlying medical conditions, recent use of gastric add inhibitors (including H2 antagonist and proton pump inhibitor), recent antibiotic therapy, antibiotic regimen for peritonitis episodes, sensitivity test results of the E. coli isolated, and clinical outcomes were examined. &#9670; Results: Over a 10-year study period, 88 episodes of E. coli peritonitis were recorded; 11 of the 88 cases were caused by ESBL-producing E. coli. Recent use of cephalosporins and gastric acid inhibitor were associated with the development of ESBL-producing E. coli peritonitis. Compared with non-ESBL-produdng E. coli peritonitis, more cases in the ESBL-producing E. coli group developed treatment failure (45.5% vs 13.0%, p = 0.02) and died of sepsis (27.3% vs 3.9%, p = 0.02). Peritoneal failure rate was higher in the ESBL-producing E. coli group, although the difference was not statistically significant (18.2% vs 3.9%, p = 0.12). &#9670; Conclusion: Peritonitis caused by ESBL-producing E. coli is associated with worse clinical outcomes. The use of cephalosporins and gastric acid inhibitors may contribute to its development. Further studies are warranted to investigate and determine the predisposing factors for ESBL-producing E. coli peritonitis. Copyright &#169; 2006 International Society for Peritoneal Dialysis.</description.abstract>
<language>eng</language>
<publisher>Multimed, Inc. The Journal&apos;s web site is located at http://pdiconnect.com</publisher>
<relation.ispartof>Peritoneal Dialysis International</relation.ispartof>
<subject>Cephalosporin</subject>
<subject>E coli</subject>
<subject>Extended-spectrum beta-lactamase</subject>
<subject>Gastric acid inhibitor</subject>
<subject>Peritonitis</subject>
<subject.mesh>Aged</subject.mesh>
<subject.mesh>Escherichia Coli - Enzymology</subject.mesh>
<subject.mesh>Escherichia Coli Infections</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Male</subject.mesh>
<subject.mesh>Middle Aged</subject.mesh>
<subject.mesh>Peritoneal Dialysis, Continuous Ambulatory</subject.mesh>
<subject.mesh>Peritonitis - Microbiology</subject.mesh>
<subject.mesh>Risk Factors</subject.mesh>
<subject.mesh>Beta-Lactamases - Biosynthesis</subject.mesh>
<title>Risk factors and outcomes of extended-spectrum beta-lactamase-producing E. coli peritonitis in CAPD patients</title>
<type>Article</type>
<description.nature>Link_to_OA_fulltext</description.nature>
<identifier.pmid>16623424</identifier.pmid>
<identifier.scopus>eid_2-s2.0-33645510764</identifier.scopus>
<identifier.hkuros>117896</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-33645510764&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>26</identifier.volume>
<identifier.issue>2</identifier.issue>
<identifier.spage>191</identifier.spage>
<identifier.epage>197</identifier.epage>
<identifier.isi>WOS:000237003600013</identifier.isi>
<publisher.place>Canada</publisher.place>
<bitstream.url>http://hub.hku.hk/bitstream/10722/162957/1/re01.htm</bitstream.url>
</item>
Author Affiliations
  1. The University of Hong Kong